doi:10.3969/j.issn.1673-8640.2018.07.013

Abstract

CLC Number:

R446.1

Figures/Tables 3

References 12

[1]	FISMAN D N.Syphilis resurgent in China[J] . Lancet,2007,369(9556):84-85.
[2]	NORRIS S J.Polypeptides of Treponema pallidum: progress toward understanding their structural, functional, and immunologic roles. Treponema Pallidum Polypeptied Research Group[J]. Microbiol Rev,1993,57(3):750-779.
[3]	DE LEMOS E A,BELÉM Z R,SANTOS A,et al. Characterization of the Western blotting IgG reactivity patterns in the clinical phases of acquired syphilis[J]. Diagn Microbiol Infect Dis,2007,58(2):177-183.
[4]	PARK B G,YOON J G,RIM J H,et al.Comparison of six automated Treponema-specific antibody assays[J]. J Clin Microbiol,2016,54(1):163-167.
[5]	SOMMESE L,SABIA C,ESPOSITO A,et al.Comparison of performance of two Treponema pallidum automated chemiluminescent immunoassays in blood donors[J]. Infect Dis(Lond), 2016,48(6):483-487.
[6]	Centers for Disease Control and Prevention (CDC). Discordant results from reverse sequence syphilis screening-five laboratories,United States,2006-2010[J]. MMWR Morb Mortal Wkly Rep,2011,60(5):133-137.
[7]	Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines,2015 [EB/OL]. (2015-06-05)[2018-03-15]. .
[8]	HOOVER K W,RADOLF J D.Serodiagnosis of syphilis in the recombinant era:reversal of fortune[J]. J Infect Dis,2011,204(9):1295-1296.
[9]	BAKER-ZANDER S A,HOOK E W 3rd,BONIN P,et al. Antigens of Treponema pallidum recognized by IgG and IgM antibodies during syphilis in humans[J]. J Infect Dis,1985,151(2):264-272.
[10]	United Nations Development Programme, World Bank,World Health Organization,et al. Laboratory-based evaluation of rapid syphilis diagnostics[R]. Geneva:WHO,2003.
[11]	SIEDNER M,ZAPITZ V,ISHIDA M,et al.Performance of rapid syphilis tests in venous and fingerstick whole blood specimens[J]. Sex Transm Dis,2004,31(9):557-560.
[12]	SEÑA A C,WHITE B L,SPARLING P F. Novel Treponema pallidum serologic tests:a paradigm shift in syphilis screening for the 21st century[J]. Clin Infect Dis,2010,51(6):700-708.

组别	例数	免疫层析法		CMIA
组别	例数	有反应性	无反应性	有反应性	无反应性
第1组	125	122	3	125	0
第2组	25	23	2	25	0
第3组	200	8	192	16	184

组别	例数	免疫层析法		CMIA
组别	例数	有反应性	无反应性	有反应性	无反应性
第1组	125	122	3	125	0
第2组	25	23	2	25	0
第3组	200	8	192	16	184

样本号		TPPA		TRUST	免疫层析法	CMIA	免疫印迹法
样本号		TPPA		TRUST	免疫层析法	CMIA	TpN15	TpN17	TpN45	TpN47	报告
1		阳性1∶80+		-	-	+	-	+	-	+/-	+
2		阳性1∶80+		-	-	+	-	+/-	-	+	+
3		阳性1∶80++		-	-	+	-	+	-	+/-	+
4		1∶80+/-		-	-	+	-	-	+	+	+
5		1∶80+/-		-	-	+	+	+/-	+/-	+/-	+
6		-		-	+/-	+	-	-	-	+	临界
7		-		-	+/-	+	-	+	+	-	+
8		-		-	+/-	-	-	-	-	-	-
9		-		-	+/-	-	-	-	+	-	临界
10		-		-	+/-	+	-	+	-	+/-	+
11		-		-	+/-	+	-	-	-	-	-
样本号	TPPA		TRUST	免疫层析法	CMIA	免疫印迹法
样本号	TPPA		TRUST	免疫层析法	CMIA	TpN15	TpN17	TpN45	TpN47	报告
12	-		-	+/-	-	-	-	-	+/-	临界
13	-		-	+/-	+	-	-	-	+/-	临界
14			-	-	+	-	+	-	-	临界
15	-		-	-	+	-	-	-	-	-
16	-		-	-	+	-	+	-	-	临界
17	-		-	-	+	+/-	-	+/-	-	+
18	-		-	-	+	+	-	-	-	临界
19	-		-	-	+	-	-	-	-	-
20	-		-	-	+	-	+	-	-	临界
21	-		-	-	+	-	+	+/-	-	+
22	-		-	-	+	-	-	-	-	-
23	-		-	-	+	-	+	+	-	+
24	-		-	-	+	-	-	-	-	-

样本号		TPPA		TRUST	免疫层析法	CMIA	免疫印迹法
样本号		TPPA		TRUST	免疫层析法	CMIA	TpN15	TpN17	TpN45	TpN47	报告
1		阳性1∶80+		-	-	+	-	+	-	+/-	+
2		阳性1∶80+		-	-	+	-	+/-	-	+	+
3		阳性1∶80++		-	-	+	-	+	-	+/-	+
4		1∶80+/-		-	-	+	-	-	+	+	+
5		1∶80+/-		-	-	+	+	+/-	+/-	+/-	+
6		-		-	+/-	+	-	-	-	+	临界
7		-		-	+/-	+	-	+	+	-	+
8		-		-	+/-	-	-	-	-	-	-
9		-		-	+/-	-	-	-	+	-	临界
10		-		-	+/-	+	-	+	-	+/-	+
11		-		-	+/-	+	-	-	-	-	-
样本号	TPPA		TRUST	免疫层析法	CMIA	免疫印迹法
样本号	TPPA		TRUST	免疫层析法	CMIA	TpN15	TpN17	TpN45	TpN47	报告
12	-		-	+/-	-	-	-	-	+/-	临界
13	-		-	+/-	+	-	-	-	+/-	临界
14			-	-	+	-	+	-	-	临界
15	-		-	-	+	-	-	-	-	-
16	-		-	-	+	-	+	-	-	临界
17	-		-	-	+	+/-	-	+/-	-	+
18	-		-	-	+	+	-	-	-	临界
19	-		-	-	+	-	-	-	-	-
20	-		-	-	+	-	+	-	-	临界
21	-		-	-	+	-	+	+/-	-	+
22	-		-	-	+	-	-	-	-	-
23	-		-	-	+	-	+	+	-	+
24	-		-	-	+	-	-	-	-	-

方法	免疫印迹法			总计^*
方法	+	-	临界	总计^*
免疫层析法	7	2	4	13
CMIA	5	5	6	16

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 12

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.